

Crowe MacKay LLP

1100 - 1177 West Hastings St. Vancouver, BC V6E 4T5

Main +1 (604) 687-4511 Fax +1 (604) 687-5805 www.crowemackay.ca

April 29, 2021

British Columbia Securities Commission Alberta Securities Commission The Manitoba Securities Commission Ontario Securities Commission

Dear Sirs/Mesdames:

Re: Defence Therapeutics Inc.

We refer to the final prospectus of Defence Therapeutics Inc. (the "Company") dated April 29, 2021 (the "Prospectus") relating to the qualification and distribution of 6,137,000 Class A common shares and 6,137,000 warrants issuable upon the deemed exercise of 6,137,000 special warrants.

We consent to being named and to the use, through inclusion in the above-mentioned Prospectus, of our report dated January 5, 2021 to the directors of the Company on the following financial statements:

statements of financial position as at June 30, 2020 and June 30, 2019;

statements of comprehensive loss, changes in equity (deficiency) and cash flows for the years ended June 30, 2020 and June 30, 2019, and a summary of significant accounting policies and explanatory information.

We report that we have read the Prospectus and all information specifically included therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

"Crowe MacKay LLP"

Chartered Professional Accountants Vancouver, British Columbia